Akèy › Lukemi miyoyid kwonik
Etid klinik pou Lukemi miyoyid kwonik ap rekrite nan Etazini
48 etid pou Lukemi miyoyid kwonik ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX18 etid
- Seattle, WA11 etid
- New York City, NY11 etid
- Detroit, MI6 etid
- Philadelphia, PA6 etid
- Portland, OR6 etid
- Birmingham, AL6 etid
- Baldwin Park, CA6 etid
- Chicago, IL6 etid
- Milwaukee, WI5 etid
- Nashville, TN5 etid
- Atlanta, GA5 etid
- Baltimore, MD5 etid
- Boston, MA5 etid
- Durham, NC5 etid
- Columbus, OH5 etid
- Augusta, GA4 etid
- St. Louis, MO4 etid
- Mountain View, CA4 etid
- Washington, DC4 etid
- Rochester, NY4 etid
- Edison, NJ4 etid
- Cincinnati, OH4 etid
- Kansas City, MO4 etid
- Minneapolis, MN3 etid
- Buffalo, NY3 etid
- Salt Lake City, UT3 etid
- Orange, CA3 etid
- St. Petersburg, FL3 etid
- Cleveland, OH3 etid
- Miami, FL3 etid
- Greenville, NC3 etid
- Bridgeport, CT3 etid
- Sacramento, CA3 etid
- Ann Arbor, MI3 etid
- Aurora, CO3 etid
Pa eta
- Alabama6 etid
- Arizona4 etid
- Colorado4 etid
- Distrik Columbia3 etid
- Florid7 etid
- Georgia7 etid
- Illinois6 etid
- Indiana3 etid
- Kalifòni10 etid
- Kansas5 etid
- Kentucky3 etid
- Maryland6 etid
- Massachusetts5 etid
- Michigan7 etid
- Minnesota4 etid
- Missouri4 etid
- Nebraska3 etid
- New Jersey4 etid
- New York15 etid
- North Carolina8 etid
- Ohio9 etid
- Oregon6 etid
- Pennsylvania7 etid
- Tennessee5 etid
- Texas18 etid
- Utah3 etid
- Virginia4 etid
- Washington11 etid
- Wisconsin5 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Oct 1, 2026 · NCT06904066Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or Asciminib
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06817720Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Ap rekriteEtid obsèvasyon
Laj 0 a 38 · Tout sèks · Mizajou Oct 1, 2026 · NCT06131801Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Ap rekriteFaz 1/2
Laj 1 a 17 · Tout sèks · Mizajou Sep 25, 2026 · NCT04925479Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07269470Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06236724Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06398457Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Ap rekriteFaz 1
Laj 1 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT03630991Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT01746836Study of Olverembatinib (HQP1351) in Patients With CML-CP
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06423911Cord Blood Transplant in Adults With Blood Cancers
Ap rekriteFaz 2
Laj 21 a 65 · Tout sèks · Mizajou Sep 11, 2026 · NCT05884333Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Ap rekriteFaz 2
Laj 1 a 18 · Tout sèks · Mizajou Sep 2, 2026 · NCT07354074Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT05334069Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT06523556Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Ap rekriteFaz 1
1 Day – 21 Years · Tout sèks · Mizajou Aug 26, 2026 · NCT05857969Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT04838041TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Ap rekriteFaz 1
Laj 18 a 80 · Tout sèks · Mizajou Aug 17, 2026 · NCT07302776Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Ap rekriteFaz 2
6 Months – 65 Years · Tout sèks · Mizajou Jul 22, 2026 · NCT06013423Allo HSCT Using RIC and PTCy for Hematological Diseases
Ap rekriteFaz 2
Jiska laj 75 · Tout sèks · Mizajou Jul 6, 2026 · NCT05805605Asciminib Roll-over Study
Ap rekriteFaz 4
Laj 7 a 100 · Tout sèks · Mizajou Jul 6, 2026 · NCT04877522A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jul 6, 2026 · NCT01351545Registry of Older Patients With Cancer
Ap rekriteEtid obsèvasyon
Laj 65 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT01137825Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Ap rekriteFaz 2
Jiska laj 60 · Tout sèks · Mizajou Jun 25, 2026 · NCT03314974Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 22, 2026 · NCT05549661Impact of Targeted Therapy on Cancer-Related Cognitive Impairment
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Jun 10, 2026 · NCT07638007Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.